Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01591681 · ClinicalTrials.gov registry record · Phase 2

Outpatient Pump Shutoff Pilot Feasibility and Efficacy Study

A Phase 2 study, sponsored by Jaeb Center for Health Research.

Completed
Registry status
Phase 2
Development phase
49
Enrollment target

NCT01591681: Completed Phase 2 study, sponsored by Jaeb Center for Health Research.

NCT01591681 is a Phase 2 study that has completed, run by Jaeb Center for Health Research. The registered enrollment target is 49 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01591681, a Phase 2 study, has completed, sponsored by Jaeb Center for Health Research.

COMPLETED
Registry status
Phase 2
Development phase
49 participants
Enrollment target

Study Summary

The purpose of this study is to see whether low blood sugar at night can be reduced by using a system that turns off the insulin pump automatically. The study system includes a combination continuous glucose monitor (CGM)/ insulin pump made by Medtronic MiniMed, Inc and a regular laptop computer that runs a computer program that predicts low blood sugar. It works by (1) measuring the glucose levels under the skin with a continuous glucose monitor, (2) using a computer program on a laptop to predict what will happen to the glucose level over the next 35-55 minutes, and (3) turning off the insulin pump when the computer program predicts that low blood sugar will occur. This study has several phases and will take about 3 months for a patient to complete. Patients will use the Medtronic CGM with the Enlite sensor at home for 10-15 days to be sure that they are able and willing to use this system and to determine if they meet the investigators study criteria to proceed with the next phase of the study. Patients will be provided teaching on how to use CGM data in real time. If a patient is not using a Medtronic CGM already, the patient will first use one at home for 10-15 days to be sure that he/she is able and willing to use it. If a patient is already using a Medtronic CGM, then his/her most recent 10-15 days of data will be used to find out if he/she is eligible. Those who need to complete the CGM run-in phase will have an extra office visit for training. If eligible to continue in the study, patients will need to use the study system for 5 nights at home so that the investigators can make sure they are able to use it correctly. After that, patients will be asked to use the study system each night for an additional 6 to 8 weeks. If the system is active and predicts that a patient's blood sugar will become low, the insulin pump will shut off for up to 2 hours. The study will include about 45 individuals at 3 clinical centers in the United States and Canada.

Primary Outcome

Each night is categorized as to whether hypoglycemia occurred. Hypoglycemia is defined as the occurrence of one or more CGM glucose values ≤60 mg/dL. The percentage of hypoglycemic nights will be tabulated separately with versus without the closed-loop control system in use. A repeated measures logistic regression model will be used to compare intervention versus control nights accounting for correlated data from the same subject and adjusting for the baseline (bedtime) sensor glucose.

Interventions

  • DEVICE Pump suspension

Trial Details

FieldValue
Enrollment Target 49 participants
Start Date 2012-11
Est. Completion 2013-07
Phase Phase 2
Jaeb Center for Health Research

119 total trials

What the finished NCT01591681 record still lists

NCT01591681 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (63% lower).

The record links to 0 conditions, and to 1 intervention - of which Pump suspension is the first listed.

NCT01591681 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01591681 about?

NCT01591681 is a clinical study titled "Outpatient Pump Shutoff Pilot Feasibility and Efficacy Study". The purpose of this study is to see whether low blood sugar at night can be reduced by using a system that turns off the insulin pump automatically. The study system includes a combination continuous glucose monitor (CGM)/ insulin pump made by Medtronic MiniMed, Inc and a regular laptop computer tha...

What is the current status of trial NCT01591681?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2012-11. Estimated completion is 2013-07.

What interventions are being tested in trial NCT01591681?

The interventions under investigation include: Pump suspension (DEVICE).

Who is sponsoring clinical trial NCT01591681?

This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01591681's enrollment target sits among peer trials

49 1261st of 2000 higher than 736 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02704858 · 49 participants · Phase 1

    Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

  • NCT03516708 · 49 participants · Phase 1

    Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer

  • NCT03692429 · 49 participants · Phase 1

    alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

  • NCT04329494 · 49 participants · Phase 1

    PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01591681, the US trial registry maintained by the National Library of Medicine. NCT01591681 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.